Latest XVIVO News & Updates

See the latest news and media coverage for XVIVO. We track all announcements, press releases, and industry mentions in real time, all in one place.

XVIVO

Organ perfusion technologies provider

Latest news about XVIVO

April 27 XVIVO

XVIVO holds Annual General Meeting

Resolutions include adopting 2025 financials, no dividend, board re-elections, new incentive program, and share issue authorizations.
April 24 XVIVO

XVIVO reports Q1 2026 financial results

Net sales reached SEK 241 million, up 10%. Organic growth was 23% in local currencies. EBIT was SEK 31.9 million. Positive cash flow achieved.
April 22 XVIVO

XVIVO presents encouraging HOPE trial results

The trial met its primary endpoint with 98% 30-day survival, low graft dysfunction, using XVIVO Heart Assist Transport for DCD hearts. Experts highlight feasibility and logistical benefits.
April 22 XVIVO

XVIVO presents preliminary one-year follow-up data from US PRESERVE trial

Data shows 92.1% success rate at 30 days and 91.4% survival at 365 days. Trial met primary endpoints for heart preservation technology.

April 27 Morningstar

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB (publ) ("XVIVO Perfusion" or the "Company") held today on...
April 24 Morningstar

Interim Report January - March 2026

GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding...
April 23 Dagens industri

Xvivo study reached primary endpoint - "very promising"

Close LIVE: Stock market morning April 23. The transplantation company Xvivo's first clinical study for direct management of DCD hearts using hypothermic oxygenated perfusion, Hope, achieved its predefined...
April 22 Morningstar

XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion...

GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were...

Never miss news about XVIVO

Track XVIVO and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Discover what's making headlines across other trending companies.